Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure

Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure

Authors

  • Vanessa Azzolina Department of Dermatology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany
  • Franziska Schauer Department of Dermatology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany
  • Julia Felicitas Pilz Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany
  • Alexander Zink Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany
  • Kilian Eyerich Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
  • Caroline Pilz Department of Dermatology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany

Keywords:

ivermectin, permethrin, scabies, treatment failure, Treatment outcome, Drug resistance, Risk factors

Abstract

Introduction: Scabies is a parasitic infectious skin disease classified as a neglected tropical disease by the World Health Organization in 2017. Currently, it is becoming a major challenge in high-income countries, with rapidly rising incidence and increasing reports about treatment failure.

Objectives: Factors that are associated with treatment failure or success were evaluated.

Methods: This non-interventional prospective observational study was conducted as a questionnaire survey at the Department of Dermatology and Venereology of the University of Freiburg from January to November 2023. Patients that still suffered from scabies 2–6 weeks after medical treatment were classified as “failure”; those who were free of scabies belonged to the success group.

Results: Of 102 participants, with a mean age of 34.4 ± 17.3 years (male: 60.4%), 77 (75.5%) were assigned to the success and 25 (24.5%) to the failure group. A larger proportion of the latter was clinically more severely affected, applied permethrin monotherapy, did not undertake special decontamination measures, but used alcohol as a disinfectant. Treatment success was associated with an additional systemic treatment, a repeated intake of ivermectin, and intensified decontamination measures such as storage of clothes in plastic bags for four days or vacuum cleaning of car seats.

Conclusions: Our findings indicate that a consistent second-dose administration of ivermectin and refraining from permethrin monotherapy may be advisable.

References

Engelman D, Cantey PT, Marks M, et al. The public health control of scabies: priorities for research and action. Lancet Lond Engl. 2019;394(10192):81-92. DOI:10.1016/S0140-6736(19)31136-5

Gopinath H, Karthikeyan K. Genital scabies: Haven of an unwelcome guest. Indian J Sex Transm Dis AIDS. 2020;41(1):10-16. DOI:10.4103/ijstd.IJSTD_69_17

Ong CY, Vasanwala FF. Infected with Scabies Again? Focus in Management in Long-Term Care Facilities. Dis Basel Switz. 2018;7(1):3. DOI:10.3390/diseases7010003

Heukelbach J, Feldmeier H. Scabies. Lancet Lond Engl. 2006;367(9524):1767-1774. DOI:10.1016/S0140-6736(06)68772-2

Chandler DJ, Fuller LC. A Review of Scabies: An Infestation More than Skin Deep. Dermatol Basel Switz. 2019;235(2):79-90. DOI:10.1159/000495290

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond Engl. 2018;392(10159):1789-1858. DOI:10.1016/S0140-6736(18)32279-7

Schneider S, Wu J, Tizek L, Ziehfreund S, Zink A. Prevalence of scabies worldwide-An updated systematic literature review in 2022. J Eur Acad Dermatol Venereol JEADV. 2023;37(9):1749-1757. DOI:10.1111/jdv.19167

World Health Organization. Scabies. March 31, 2023. Accessed June 3, 2024. https://www.who.int/news-room/fact-sheets/detail/scabies

Zhang W, Zhang Y, Luo L, et al. Trends in prevalence and incidence of scabies from 1990 to 2017: findings from the global Burden of disease study 2017. Emerg Microbes Infect. 2020;9(1):813-816. DOI:10.1080/22221751.2020.1754136

Amato E, Dansie LS, Grøneng GM, et al. Increase of scabies infestations, Norway, 2006 to 2018. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2019;24(23):190020. DOI:10.2807/1560-7917.ES.2019.24.23.190020

Reichert F, Schulz M, Mertens E, Lachmann R, Aebischer A. Reemergence of Scabies Driven by Adolescents and Young Adults, Germany, 2009-2018. Emerg Infect Dis. 2021;27(6):1693-1696. DOI:10.3201/eid2706.203681

Balestri R, Magnano M, Infusino SD, Rizzoli L, Girardelli CR, Rech G. Scabies is becoming less sensitive to permethrin therapy. J Eur Acad Dermatol Venereol JEADV. 2021;35(12):e889-e891. DOI:10.1111/jdv.17538

Mazzatenta C, Piccolo V, Argenziano G, Bassi A. Is Scabies becoming less sensitive to permethrin therapy? J Eur Acad Dermatol Venereol JEADV. 2021;35(9):e607-e609. DOI:10.1111/jdv.17339

Rinaldi F, Chirico R, Trink A, Pinto D. Resistance and Pseudo-resistance to permethrin: the importance of controlling scabies. Front Cell Infect Microbiol. 2023;13:1297337. DOI:10.3389/fcimb.2023.1297337

Sunderkötter C, Feldmeier H, Fölster-Holst R, et al. S1-Leitlinie zur Diagnostik und Therapie der Skabies - Kurzfassung - PubMed. Accessed June 3, 2024. https://pubmed.ncbi.nlm.nih.gov/27879080/

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. DOI:10.1016/j.jbi.2008.08.010

The REDCap consortium: Building an international community of software platform partners - PubMed. Accessed June 3, 2024. https://pubmed.ncbi.nlm.nih.gov/31078660/

Aussy A, Houivet E, Hébert V, et al. Risk factors for treatment failure in scabies: a cohort study. Br J Dermatol. 2019;180(4):888-893. DOI:10.1111/bjd.17348

Sanei-Dehkordi A, Soleimani-Ahmadi M, Zare M, Jaberhashemi SA. Risk factors associated with scabies infestation among primary schoolchildren in a low socio-economic area in southeast of Iran. BMC Pediatr. 2021;21(1):249. DOI:10.1186/s12887-021-02721-0

McCarthy J, Kemp D, Walton S, Currie B. Scabies: more than just an irritation. Postgrad Med J. 2004;80(945):382-387. DOI:10.1136/pgmj.2003.014563

Morrison EJ, Middleton J, Lanza S, et al. Do we know how scabies outbreaks in residential and nursing care homes for the elderly should be managed? A systematic review of interventions using a novel approach to assess evidence quality. Epidemiol Infect. 2019;147:e250. DOI:10.1017/S0950268819001249

Blaizot R, Armanville F, Michaud C, et al. Scabies in French Guiana: Quantitative and qualitative factors associated with therapeutic failure. J Eur Acad Dermatol Venereol JEADV. 2024;38(3):602-612. DOI:10.1111/jdv.19688

Meyersburg D, Hoellwerth M, Brandlmaier M, et al. Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial. Br J Dermatol. 2024;190(4):486-491. DOI:10.1093/bjd/ljad501

Riebenbauer K, Purkhauser K, Walochnik J, et al. Detection of a knockdown mutation in the voltage-sensitive sodium channel associated with permethrin tolerance in Sarcoptes scabiei var. hominis mites. J Eur Acad Dermatol Venereol JEADV. 2023;37(11):2355-2361. DOI:10.1111/jdv.19288

Steer AC, Kearns T, Andrews RM, McCarthy JS, Carapetis JR, Currie BJ. Ivermectin worthy of further investigation. Bull World Health Organ. 2009;87(10):A. DOI:10.2471/BLT.09.070540

Balestri R, Magnano M, Infusino SD, Girardelli CR, Ioris T, Rech G. Oral ivermectin to treat scabies: a comparison of two different regimens. Clin Exp Dermatol. 2023;48(3):232-234. DOI:10.1093/ced/llac092

Mbuagbaw L, Sadeghirad B, Morgan RL, et al. Failure of scabies treatment: a systematic review and meta-analysis. Br J Dermatol. 2024;190(2):163-173. DOI:10.1093/bjd/ljad308

Lehmann P, Kremer A, Assmann T, Mang R. Pruritic papules and nodules as sign of persistent scabies infestation despite treatment according to current guidelines evidence for treatment resistance to ivermectin, benzylbenzoat and permethrin proven by videomicroscopy. IDCases. 2023;31:e01678. DOI:10.1016/j.idcr.2023.e01678

Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Dermatol. 2009;145(7):840-841. DOI:10.1001/archdermatol.2009.125

Mounsey KE, Pasay CJ, Arlian LG, et al. Increased transcription of Glutathione S-transferases in acaricide exposed scabies mites. Parasit Vectors. 2010;3:43. DOI:10.1186/1756-3305-3-43

InfectoPharm Arzneimittel. Fachinformation. InfectoScab® 5% Creme. 2021. Accessed June 4, 2024. https://data-storage.live/data/unsec/fi-infectoscab.pdf

Cinotti E, Perrot JL, Labeille B, et al. Inefficacy of alcohol-based hand rub on mites in a patient with hyperkeratotic scabies. Clin Exp Dermatol. 2015;40(2):177-181. DOI:10.1111/ced.12467

Downloads

Published

2025-04-30

How to Cite

1.
Azzolina V, Schauer F, Pilz JF, Zink A, Eyerich K, Pilz C. Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure. Dermatol Pract Concept. 2025;15(2):5077. doi:10.5826/dpc.1502a5077

Share